<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00155272</url>
  </required_header>
  <id_info>
    <org_study_id>931003</org_study_id>
    <nct_id>NCT00155272</nct_id>
  </id_info>
  <brief_title>Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>A Pilot Clinical and Mechanistic Study of Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <brief_summary>
    <textblock>
      This is a pilot study of concomitant radiotherapy and thalidomide for patients with locally&#xD;
      advanced HCC.Besides toxicity and efficacy, mechanistic studies including dynamic contrast&#xD;
      enhanced MRI and serum cytokines will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study of concomitant radiotherapy and thalidomide for patients with locally&#xD;
      advanced HCC. Patients whose tumor(s) are not suitable for other local treatment, such as&#xD;
      surgery, trans-arterial chemoembolization (TAE), ethanol injection, or radiofrequency&#xD;
      ablation. will be enrolled.Radical radiotherapy will be started after pre-treatment&#xD;
      evaluation. The total dose of RT will be 50Gy in 25 fractions to local tumor(s). Oral&#xD;
      Thalidomide will be started 3 days before RT begins. Thalidomide treatment will continue for&#xD;
      totally 6 months or until tumor progression. Dynamic contrast enhanced MRI (DCEMRI) will be&#xD;
      done at the following time points to assess the change in tumor perfusion: (1) before the&#xD;
      start of thalidomide treatment; (2) 3 days after thalidomide before radiotherapy; (3) 2weeks&#xD;
      after radiotherapy begins;and (4) 1 month after radiotherapy completes. DCEMRI will then be&#xD;
      done every 3 months until disease progression.Serum samples for angiogenic cytokine studies&#xD;
      will also be collected.The study was designed to evaluate the feasibility and tolerability of&#xD;
      combination treatment of radiotherapy and thalidomide for locally advanced HCC. The sample&#xD;
      size was determined by the expected incidence of grade 4 toxicity of the combination&#xD;
      treatment versus radiotherapy alone for locally advanced HCC. Since the grade 4 toxicity of&#xD;
      radiotherapy alone is 7-9%, we need at least 15 patients to evaluate for feasibility of the&#xD;
      combination treatment. With an estimated drop out rate of approximately 10%, 17 patients will&#xD;
      be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2005</start_date>
  <completion_date>August 2005</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the feasibility and tolerability of thalidomide plus radiotherapy.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary end point is correlation of parameters of tumor perfusion assessed by DCEMRI and serum cytokine levels with objective tumor response.</measure>
  </secondary_outcome>
  <enrollment>19</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.1 Patients with measurable, locally advanced HCC that are not suitable for other&#xD;
             local therapies, including surgery, TAE, alcohol injection, or radiofrequency&#xD;
             ablation.&#xD;
&#xD;
        1.2 Patients with histological confirmed HCC or patients who do not have histological&#xD;
        diagnosis but have met all of the following criteria: 1.2.1 Presence of chronic viral&#xD;
        hepatitis and/or cirrhosis 1.2.2 Presence of hepatic tumor(s) with image findings&#xD;
        (sonography, CT scan) compatible with HCC.&#xD;
&#xD;
        1.2.3 A persistent elevation of serum a-fetoprotein level ³ 400 ng/ml without any evidence&#xD;
        of ana-fetoprotein-secreting germ cell tumor.&#xD;
&#xD;
        1.3 Patients without any local or systemic therapy for HCC within 4 weeks. 1.4 Patients&#xD;
        with age &gt; 20 years and &lt; 70 years. 1.5 Patients with a performance status of ECOG score &lt;&#xD;
        1. 1.6 Patients must fulfill all of the following criteria: 1.6.1 Child-Pugh's Score ≦ 7.&#xD;
        1.6.2 Serum total bilirubin &lt; 1.5 times upper normal limit (UNL 1.6.3 Serum alanine&#xD;
        transaminase (ALT) &lt; 5 times UNL 1.6.4 Platelet count &gt; 5.0 x 104 / mm3. 1.6.5 White blood&#xD;
        cell count &gt; 3,000 / mm3. 1.6.6 Serum creatinine &lt; 2.0 mg/dL 1.7 Patient must have local&#xD;
        tumors less than one half of the whole liver and the tumors can be encompassed within RT&#xD;
        fields 1.8 Signed informed consent 1.9 Sexually active patients, in conjunction with their&#xD;
        partner, must practice birth control during, and for 2 months after, thalidomide therapy.&#xD;
&#xD;
        1.10 Female patients in child-bearing age must have negative pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  2.1. Patients with documented extrahepatic metastasis. 2.2. Patients who received&#xD;
             previous radiotherapy to abdominal area. 2.3. Patients who have received thalidomide&#xD;
             treatment prior to enrollment. 2.4. Patients who had other investigational drug&#xD;
             treatment within 4 weeks prior to enrollment.&#xD;
&#xD;
        2.5. Patients with NCI grade 2 or greater peripheral neuropathy of any causes. 2.6.&#xD;
        Patients with other systemic diseases that required concurrent usage of glucocorticosteroid&#xD;
        or immunosuppressant agent(s).&#xD;
&#xD;
        2.7. Patients who have major systemic diseases that the attending physicians consider&#xD;
        inappropriate for radiotherapy or thalidomide therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui-Ju Ch'ang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Health Research Institutes, Division of Cancer Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chih-Hung Hsu, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tiffany Ting Fang Shih, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu-Chieh Yu, R.N.</last_name>
    <phone>23123456</phone>
    <phone_ext>7658</phone_ext>
    <email>ntuhccw@nhri.org.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui-Ju Ch'ang, M.D.</last_name>
    <phone>23123456</phone>
    <phone_ext>2959</phone_ext>
    <email>hjmc@nhri.org.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NTUH</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui-Ju Ch'ang, M.D.</last_name>
      <phone>23123456</phone>
      <phone_ext>2959</phone_ext>
      <email>hjmc@nhri.org.tw</email>
    </contact>
    <investigator>
      <last_name>Hui-Ju Ch'ang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2005</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>September 8, 2005</last_update_submitted>
  <last_update_submitted_qc>September 8, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2005</last_update_posted>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Dynamic contrast enhanced MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

